<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920190</url>
  </required_header>
  <id_info>
    <org_study_id>20160568</org_study_id>
    <nct_id>NCT02920190</nct_id>
  </id_info>
  <brief_title>Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat</brief_title>
  <official_title>Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn about the effect of Liraglutide (Victoza) on&#xD;
      the fat of the heart and some fat cells in blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funds to cover the costs of the study medications&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Epicardial Fat Thickness</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Epicardial fat thickness measured in mm via ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum immunoglobulins</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Immunoglobin levels assessed in g/L will be evaluated using serum blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma ceramide levels</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Plasma ceramide levels will be evaluated in umol/L</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Monoclonal Gammopathies</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Liraglutide Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive the Liraglutide intervention for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months</description>
    <arm_group_label>Liraglutide Group</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI ≥27 kg/m2&#xD;
&#xD;
          -  At least one overweight/obesity related comorbidity (such as type 2 diabetes,&#xD;
             pre-diabetes [IFG, IGT], hypertension, dyslipidemia)&#xD;
&#xD;
          -  Age &gt; 18 and &lt; 70 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known contra-indications to Liraglutide, such as previous history of pancreatitis or&#xD;
             medullary thyroid carcinoma, personal or family history of MEN, in accordance with&#xD;
             risks and safety information included in the latest updated Prescribing Information&#xD;
             for Victoza®&#xD;
&#xD;
          -  Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria&#xD;
&#xD;
          -  Insulin dependent or treated type 2 diabetes&#xD;
&#xD;
          -  Current use of other injectable incretins&#xD;
&#xD;
          -  History of diabetes ketoacidosis&#xD;
&#xD;
          -  Advanced Chronic Kidney Disease, as defined by Glomerular Filtration Rate (GFR) &lt; 30&#xD;
             mL/min/1.73m2&#xD;
&#xD;
          -  Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV heart&#xD;
             failure&#xD;
&#xD;
          -  Clinical or laboratory evidences of chronic active liver diseases&#xD;
&#xD;
          -  Acute or chronic infective diseases&#xD;
&#xD;
          -  Known or suspected allergy to Liraglutide, excipients, or related products&#xD;
&#xD;
          -  Pregnant, breast-feeding or the intention of becoming pregnant&#xD;
&#xD;
          -  Females of childbearing potential who are not using adequate contraceptive methods&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Hoffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>James Hoffman, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

